Lucira Health Inc
NASDAQ:LHDX
Intrinsic Value
Lucira Health, Inc. provides DNA testing services for medical, forensics, chemical, industrial, and agricultural applications. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of LHDX.
Fundamental Analysis
Balance Sheet Decomposition
Lucira Health Inc
| Current Assets | 120.5m |
| Cash & Short-Term Investments | 39.8m |
| Receivables | 19.2m |
| Other Current Assets | 61.5m |
| Non-Current Assets | 68.7m |
| PP&E | 66m |
| Other Non-Current Assets | 2.7m |
| Current Liabilities | 82.5m |
| Accounts Payable | 25.2m |
| Accrued Liabilities | 55m |
| Other Current Liabilities | 2.4m |
| Non-Current Liabilities | 45.8m |
| Long-Term Debt | 29.4m |
| Other Non-Current Liabilities | 16.4m |
Earnings Waterfall
Lucira Health Inc
|
Revenue
|
212.1m
USD
|
|
Cost of Revenue
|
-246.1m
USD
|
|
Gross Profit
|
-34m
USD
|
|
Operating Expenses
|
-102.9m
USD
|
|
Operating Income
|
-136.9m
USD
|
|
Other Expenses
|
-6.4m
USD
|
|
Net Income
|
-143.3m
USD
|
Free Cash Flow Analysis
Lucira Health Inc
LHDX Profitability Score
Profitability Due Diligence
Lucira Health Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
Score
Lucira Health Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
LHDX Solvency Score
Solvency Due Diligence
Lucira Health Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Lucira Health Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LHDX Price Targets Summary
Lucira Health Inc
Ownership
LHDX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
LHDX Price
Lucira Health Inc
| Average Annual Return | -48.06% |
| Standard Deviation of Annual Returns |
N/A
|
| Max Drawdown | -100% |
| Market Capitalization | 1.4m USD |
| Shares Outstanding | 40 599 000 |
| Percentage of Shares Shorted | 3.77% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Lucira Health, Inc. provides DNA testing services for medical, forensics, chemical, industrial, and agricultural applications. The company is headquartered in Emeryville, California and currently employs 141 full-time employees. The company went IPO on 2021-02-05. The firm is focused on the development and commercialization of transformative and infectious disease test kits. The firm has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and test kit that is powered by two AA batteries and fit in the palm of a hand. Its initial focus is within respiratory diseases, starting with COVID-19 and influenza A and B virus indications. The company has developed LUCIRA COVID-19 All-In-One Test Kit (COVID-19 test kit), is a single-use, molecular in vitro diagnostic test that has an analytical sensitivity to detect the SARS-CoV-2 virus. The test is authorized for prescription at-home use.
You don't have any saved screeners yet
